Potent and selective S1P5
values are 4.1 and 5.7 nM in cAMP and GTPγ
S assays, respectively). Exhibits 60-fold selectivity over S1P1
, and >1,600-fold selectivity over S1P2-4
, and a panel of 129 kinases and 79 receptors. Improves blood-brain barrier integrity in vitro
and reverses age-related cognitive decline in vivo
. Orally available.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Discovery of A-971432, an orally bioavailable selective sphingosine-1-phosphate receptor 5 (S1P5) agonist for the potential treatment of neurodegenerative disorders.
Hobson et al.